Cambridge Investment Research Advisors, Inc. Immunity Bio, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $36.4 Billion
- Q3 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 70,290 shares of IBRX stock, worth $146,203. This represents 0.0% of its overall portfolio holdings.
Number of Shares
70,290
Previous 20,950
235.51%
Holding current value
$146,203
Previous $55,000
214.55%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding IBRX
# of Institutions
298Shares Held
137MCall Options Held
2.59MPut Options Held
3.35M-
Vanguard Group Inc Valley Forge, PA27.7MShares$57.5 Million0.0% of portfolio
-
Jane Street Group, LLC New York, NY12.8MShares$26.7 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$23.8 Million0.0% of portfolio
-
State Street Corp Boston, MA11.3MShares$23.5 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.89MShares$14.3 Million0.0% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $833M
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...